NovoCure Limited Profile Avatar - Palmy Investing

NovoCure Limited

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and G…

Medical - Instruments & Supplies
JE, Saint Helier [HQ]

FA

Fundamental Analysis · Most Recent Quarter

It is important to understand the FA Algorithm and the criterias before valuing it as a top-tier resource.

Read Rationale
Framework:
Valuation 43% Somewhat Weak
Profitability n.A. n.A.
Fin. Growth 67% Positive
Leverage & Liquidity 17% Weak
Per Share Metrics 33% Weak
Fin. Health n.A. n.A.
Fundamentals

Valuation

Metric Q4 Q1 Δ in %
EV/EBITDA 89.16 -46.58 -429.73
Graham Fair Price -9.90 5.22 5.79
PEG -69.79 0.59 1.95
Price/Book 4.93 4.62 4.41
Price/Cash Flow 48.71 -38.32 -74.71
Prices/Earnings -26.35 -10.72 -8.48
Price/Sales 0.48 12.00 11.94
Price/FCF 48.71 -38.32 -74.71
Naive Interpretation member
01 - Valuation · Somewhat Weak
Fundamentals

Profitability

Metric Q4 Q1 Δ in %
Gross Profit Margin 0.01 0.76 0.76
Operating Margin 22.45 -0.30 -0.39
ROA 15.86 -0.03 -0.04
ROE -0.13 -0.11 16.95
ROIC -0.07 -0.05 24.47
Naive Interpretation member
02 - Profitability · Not Interpreted
Fundamentals

Financial Growth

Metric Q4 Q1 Δ in %
Debt QOQ < 0.005 0.01 -84.33
Dividends QOQ 0.00 0.00 0.00
EBIT QOQ 0.11 0.20 75.88
EPS QOQ 0.04 0.18 318.18
FCF QOQ 0.20 -1.03 426.46
Revenue QOQ 0.05 0.04 -30.51
Naive Interpretation member
03 - Financial Growth · Positive
Fundamentals

Leverage & Liquidity

Metric Q4 Q1 Δ in %
Assets Turnover n.A. n.A. n.A.
Days Inventory Outstanding (DIO) 105.47 113.25 7.37
Days Sales Outstanding (DSO) 51.88 56.25 8.44
Inventory Turnover 0.85 0.79 -6.87
Debt/Capitalization 0.63 0.65 4.19
Quick Ratio 5.51 5.97 8.28
Naive Interpretation member
04 - Leverage & Liquidity · Weak
Fundamentals

Per Share Metrics

Metric Q4 Q1 Δ in %
Book Value 3.39 3.35 -1.13
Cash 8.51 8.11 -4.70
Capex -0.06 -0.11 -72.31
Free Cash Flow -0.20 -0.40 -102.27
Revenue 1.25 1.29 3.25
Naive Interpretation member
05 - Per Share Metrics · Weak
Fundamentals

Financial Health

Metric Q4 Q1 Δ in %
Current Ratio 5.78 6.26 8.36
Debt/Assets n.A. n.A. n.A.
Debt/Equity n.A. n.A. n.A.
Net Debt/EBITDA -78.22 -3.66 95.33
Naive Interpretation Member
06 - Financial Health · Bad
End of NVCR's Analysis
CIK: 1645113 CUSIP: G6674U108 ISIN: JE00BYSS4X48 LEI: - UEI: -
Secondary Listings
NVCR has no secondary listings inside our databases.